Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs

BACKGROUND: Biologic and targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies are used in management of psoriatic arthritis (PsA). Although previous studies have demonstrated that rates of adherence, persistence, discontinuation, and switching, as well as health care costs, ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Murage, Mwangi J, Princic, Nicole, Park, Julie, Malatestinic, William N, Zhu, Baojin, Atiya, Bilal, Kern, Scott A, Stenger, Keri B, Sprabery, Aubrey Trevelin, Ogdie, Alexis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373003/
https://www.ncbi.nlm.nih.gov/pubmed/35098751
http://dx.doi.org/10.18553/jmcp.2022.28.2.206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373003/
https://www.ncbi.nlm.nih.gov/pubmed/35098751
http://dx.doi.org/10.18553/jmcp.2022.28.2.206

Ejemplares similares